HC Q study #51
See all studies
Late treatment study
Sbidian et al., medRxiv, doi:10.1101/2020.06.16.20132597 (Preprint)
Hydroxych loroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
Retrospective of 4,642 hospitalized patients in France showing significantly faster discharge with HC Q and HC Q+AZ. No significant effect is seen on 28-day mortality, however many more control patients are still in hospital at 28 days suggesting there will be a significant improvement when extending past 28 days. Note that the median age is higher in the group not treated with HC Q or AZ. For other issues with the adjustments see [1]. Also see the analysis here [2]. We received feedback from one person that thinks the trial should be considered negative because the control patients still in hospital should be disregarded. However, based on other studies, it seems very likely that a significant number of deaths in the control group occurred past 28 days whereas no treated patients remained in hospital. This should be simple for the authors to resolve by extending the analysis. Even if we ignore this, it still shows significantly faster discharge for treatment, so we do not see how we can consider it negative. We note that the substantial reduction in hospital time is a very large cost reduction and may lower mortality in general by reducing the chance of exceeding maximum capacity. Additional feedback is welcome.
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.